CD274 and non-small cell lung carcinoma: In AMBER part 2B, the safety and efficacy of the combination of cobolimab plus dostarlimab across three separate cobolimab doses was assessed in patients with locally advanced or metastatic NSCLC who had previously been treated with anti–PD-(L)1 therapy and who may have received multiple lines of therapy.